智通财经网·2025-12-12 11:42Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., has received approval from the National Medical Products Administration to conduct clinical trials for Ketorolac patches, indicating a significant step in the development of this pain relief medication [1] Group 1: Clinical Trial Approval - The approval allows for the initiation of Phase III clinical trials for the Ketorolac patches in China once conditions are met [1] - The drug is classified as a chemical medication and is intended for pain relief and anti-inflammatory treatment for various conditions [1] Group 2: Indications for Use - The Ketorolac patches are primarily aimed at treating pain and inflammation associated with conditions such as lower back pain, osteoarthritis, shoulder periarthritis, tendonitis, and muscle pain [1] - Additionally, the patches are indicated for local pain relief in rheumatoid arthritis [1]